Lv1
80 积分 2024-04-03 加入
Does the presence of a micropapillary component predict worse prognosis in pathological stage IA lung adenocarcinoma?
2天前
已完结
Evolving systemic management of urothelial cancers
7天前
已完结
Antibody–drug conjugates in urothelial carcinoma: current status and future
7天前
已完结
Treatment of Advanced or Metastatic Urothelial Cancer
7天前
已完结
Antibody–drug conjugates for non-muscle invasive bladder cancer: current status and future development
7天前
已完结
Future directions for antibody-drug conjugates in urothelial cancer
7天前
已完结
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non–small cell lung cancer
9天前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
17天前
已完结
Comparison of three-weekly and six-weekly pembrolizumab United Kingdom prescribing practice for advanced and resected melanoma
23天前
已完结
Difficult Decisions in the Multidisciplinary Treatment of Resectable Non-small Cell Lung Cancer
30天前
已完结
皖公网安备34019202002308
